
|Videos|July 27, 2015
The Lessons of High Cost Specialty Drug Product Launches
Author(s)Davy James, Managing Editor
David D'Altorio, PharmD, senior vice president of health services at MedImpact Healthcare Systems, Inc, discusses takeaways from the impact of high cost drug launches on specialty pharmacy.
Advertisement
David D'Altorio, PharmD, senior vice president of health services at MedImpact Healthcare Systems, Inc, discusses takeaways from the impact of high cost drug launches on specialty pharmacy.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Eli Lilly, Novo Nordisk Strike MFN Deals With Trump Administration to Lower GLP-1 Prices
2
Oral Semaglutide Shows Promise for Weight Loss and Cardiometabolic Health
3
FDA Grants Orphan Drug Status to Immunotherapy for Acute Myeloid Leukemia Treatment
4
MFN, DTC, and the Policy Pressure Cooker: Reshaping the US Drug Market
5












































































































































































































